R3T4+AOD-9604

$109.99

R3T4 5 mg + AOD-9604 5 mg – Research Bundle


What is RETA-AOD-BLEND

Retatrutide 5 mg + AOD-9604 5 mg – Research Bundle is supplied strictly for laboratory research and analytical applications. Components are packaged separately (not pre-mixed) to support controlled comparative research workflows.

Bundle Includes:
  • 1 × Retatrutide 5 mg vial
  • 1 × AOD-9604 5 mg vial
Specifications:
  • Strength: 10 mg per vial
  • Format: Lyophilized powder
  • Category: Cellular & Regulatory Signaling
  • Documentation: COA available

Research Use Only — Not for Human Consumption.

1000 in stock

SKU: VE-RETA-AOD-BLEND Categories: ,

Description

  • About Retatrutide + AOD-9604

    This blend combines Retatrutide, AOD-9604 for controlled laboratory investigation where multi-target signaling is being characterized. Researchers may examine how these components map onto multi-pathway incretin signaling and adjacent pathways under standardized assay conditions. Common study themes include energy balance and nutrient partitioning, visceral adipose tissue biology, and metabolic adaptation over time across in‑vitro and non-clinical research models.

    Formulation choices can support comparative experiments, helping teams evaluate pathway selectivity, kinetics, and assay reproducibility. Documentation such as SDS/MSDS and lot-specific analysis may be reviewed prior to handling. This material is provided strictly for research use only and is not intended for human or veterinary consumption.

    COMMON RESEARCH APPLICATIONS

    Triple Incretin + Lipolysis Pathway Co-Activation
    Used in 3T3-L1 adipocyte and hepatocyte models to study simultaneous GIPR/GLP-1R/GCGR activation (retatrutide component) alongside AOD-9604-mediated β₃-AR lipolytic signaling, enabling characterization of additive vs. synergistic lipid mobilization and energy expenditure pathway responses.

    Hepatic Steatosis & Lipid Oxidation Research
    Used in HepG2 and AML12 hepatocyte models under lipid overload conditions to study the combined effect of triple incretin receptor activation and β-HSD-inhibitor-like lipolytic signaling on PPAR-α/CPT1A fatty acid oxidation, TG accumulation reduction, and FGF21 secretion.

    Hypothalamic Appetite & Energy Balance Circuit Studies
    Used in hypothalamic neuronal models (N41, GT1-7) to study triple GLP-1R/GIPR/GCGR agonist-driven POMC/CART upregulation and NPY/AgRP suppression in the arcuate nucleus alongside AOD-9604-associated GH pathway modulation for integrated appetite-metabolism axis research.

    Combination Metabolic Agent Benchmarking
    Benchmarked in parallel with individual components (retatrutide alone, AOD-9604 alone, and semaglutide) and against other combination approaches (CagriSema, tirzepatide) to characterize the specific receptor combination contributions to lipid mobilization, appetite suppression, and metabolic pathway endpoints.

  • Chemical Identity

    Compound Name: Retatrutide + AOD-9604

    Internal Catalog Code: Retatrutide + AOD-9604

    CAS Number: 2381089-83-2; 221231-10-3

    Molecular Formula: C221H342N46O68 • XNa; C78H123N23O23S2

    Molecular Weight: 4731.3; 1815.08 g/mol

    Physical Properties

    Form/Appearance: Lyophilized powder

    Quality & Testing

    Purity: As listed on lot-specific COA

    Testing Method : HPLC (as applicable) · identity confirmation per COA

    Verification

    COA: Lot-specific, included with order (QR on label)

    Handling & Storage

    Storage Temperature: −20°C (long-term) · 4°C (short-term)

    Light Sensitivity: Protect from light

    Moisture: Store desiccated when applicable

    Available Strengths: 5 mg

    SKU (5 mg): VE-RETA-AOD-BLEND

Reviews

There are no reviews yet.

Be the first to review “R3T4+AOD-9604”

Your email address will not be published. Required fields are marked *